studies

hepatocell cancer (HCC), atezolizumab plus bevacizumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMbrave-150, 2020 0.58 [0.42; 0.80] 0.58[0.42; 0.80]IMbrave-150, 202010%501NAnot evaluable progression or deaths (PFS)detailed resultsIMbrave-150, 2020 0.59 [0.46; 0.75] 0.59[0.46; 0.75]IMbrave-150, 202010%501NAnot evaluable objective responses (ORR)detailed resultsIMbrave-150, 2020 2.77 [1.62; 4.73] 2.77[1.62; 4.73]IMbrave-150, 202010%501NAnot evaluable AE (any grade)detailed resultsIMbrave-150, 2020 0.70 [0.14; 3.50] 0.70[0.14; 3.50]IMbrave-150, 202010%485NAnot evaluable AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.06 [0.72; 1.55] 1.06[0.72; 1.55]IMbrave-150, 202010%485NAnot evaluable AE leading to death (grade 5)detailed resultsIMbrave-150, 2020 0.78 [0.33; 1.82] 0.78[0.33; 1.82]IMbrave-150, 202010%485NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMbrave-150, 2020 1.61 [0.88; 2.92] 1.61[0.88; 2.92]IMbrave-150, 202010%485NAnot evaluable SAE (any grade)detailed resultsIMbrave-150, 2020 1.38 [0.92; 2.07] 1.38[0.92; 2.07]IMbrave-150, 202010%485NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.12; 1.90] 0.47[0.12; 1.90]IMbrave-150, 202010%485NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.16 [0.02; 1.51] 0.16[0.02; 1.51]IMbrave-150, 202010%485NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.07 [0.32; 3.53] 1.07[0.32; 3.53]IMbrave-150, 202010%485NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 1.05] 0.12[0.01; 1.05]IMbrave-150, 202010%485NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Cough AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.31 [0.09; 1.11] 0.31[0.09; 1.11]IMbrave-150, 202010%485NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.34 [0.12; 1.01] 0.34[0.12; 1.01]IMbrave-150, 202010%485NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 2.61] 0.12[0.01; 2.61]IMbrave-150, 202010%485NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.63 [0.14; 2.84] 0.63[0.14; 2.84]IMbrave-150, 202010%485NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.75 [0.24; 2.34] 0.75[0.24; 2.34]IMbrave-150, 202010%485NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.29 [0.73; 2.28] 1.29[0.73; 2.28]IMbrave-150, 202010%485NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.39 [0.61; 3.18] 1.39[0.61; 3.18]IMbrave-150, 202010%485NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMbrave-150, 2020 2.91 [0.64; 13.19] 2.91[0.64; 13.19]IMbrave-150, 202010%485NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMbrave-150, 2020 7.75 [0.44; 135.83] 7.75[0.44; 135.83]IMbrave-150, 202010%485NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.03; 7.61] 0.47[0.03; 7.61]IMbrave-150, 202010%485NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.02 [0.00; 0.28] 0.02[0.00; 0.28]IMbrave-150, 202010%485NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsIMbrave-150, 2020 4.86 [0.62; 38.30] 4.86[0.62; 38.30]IMbrave-150, 202010%485NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.17; 5.23] 0.95[0.17; 5.23]IMbrave-150, 202010%485NAnot evaluable Rash AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.06 [0.00; 1.10] 0.06[0.00; 1.10]IMbrave-150, 202010%485NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.23; 3.84] 0.95[0.23; 3.84]IMbrave-150, 202010%485NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.09; 10.54] 0.95[0.09; 10.54]IMbrave-150, 202010%485NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-01 16:05 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 234,40,132,131,133 - treatments: 602

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons